Benjamin Edwards Inc. Buys 1,363 Shares of Stryker Co. (NYSE:SYK)

Benjamin Edwards Inc. grew its holdings in Stryker Co. (NYSE:SYK - Free Report) by 1.0% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 142,039 shares of the medical technology company's stock after buying an additional 1,363 shares during the period. Stryker accounts for approximately 0.7% of Benjamin Edwards Inc.'s portfolio, making the stock its 28th largest position. Benjamin Edwards Inc.'s holdings in Stryker were worth $51,154,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. J. W. Coons Advisors LLC boosted its stake in Stryker by 0.7% in the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock worth $1,315,000 after purchasing an additional 26 shares during the period. Mascoma Wealth Management LLC lifted its holdings in shares of Stryker by 22.7% in the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock valued at $53,000 after purchasing an additional 27 shares in the last quarter. Opal Wealth Advisors LLC boosted its position in shares of Stryker by 1.6% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after buying an additional 28 shares during the period. Lindbrook Capital LLC raised its position in Stryker by 2.0% during the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock valued at $507,000 after buying an additional 28 shares during the period. Finally, Capital & Planning LLC lifted its stake in Stryker by 3.6% in the 4th quarter. Capital & Planning LLC now owns 841 shares of the medical technology company's stock worth $304,000 after acquiring an additional 29 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Buying and Selling at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 5.90% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on SYK shares. Stifel Nicolaus increased their price target on shares of Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research report on Wednesday, January 29th. Citigroup reiterated a "buy" rating and issued a $450.00 target price on shares of Stryker in a research report on Wednesday, February 26th. Barclays upped their price target on shares of Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Royal Bank of Canada lifted their price objective on Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $442.00 target price on shares of Stryker in a research report on Friday, March 21st. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $425.84.

Stryker Stock Performance

NYSE SYK traded down $3.59 during trading on Tuesday, hitting $377.77. The company's stock had a trading volume of 2,082,662 shares, compared to its average volume of 1,358,392. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The firm has a market cap of $144.19 billion, a P/E ratio of 48.68, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The firm has a 50 day moving average price of $365.95 and a 200 day moving average price of $374.03. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to analysts' expectations of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.50 EPS. Equities research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were paid a dividend of $0.84 per share. The ex-dividend date of this dividend was Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.89%. Stryker's dividend payout ratio is 45.41%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.